Dimethyl-Fumarate

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1784 publications

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.

Journal: Neurology

Published: April 06, 2026

Reviewer Comment on Zubkow et al. "Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis".

Reviewer Comment on Zubkow et al. "Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis".

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: March 27, 2026

Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.

Disease Activity Following Cessation of Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis.

Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Published: March 25, 2026

Dimethyl Fumarate Reverses β-Adrenoceptor-Mediated Myocardial Fibrosis in Mice by Inhibiting Yes-Associated Protein-Regulated Expression of Intermediate-Conductance Ca2+-Activated K+ Channel in Fibroblasts.

Dimethyl Fumarate Reverses β-Adrenoceptor-Mediated Myocardial Fibrosis in Mice by Inhibiting Yes-Associated Protein-Regulated Expression of Intermediate-Conductance Ca2+-Activated K+ Channel in Fibroblasts.

Journal: Journal of the American Heart Association

Published: March 18, 2026

Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration.

Emerging strategies in drug repurposing for decreasing the risk of age-related macular degeneration.

Journal: Expert opinion on drug discovery

Published: March 10, 2026

Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics.

Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics.

Journal: Redox biology

Published: February 16, 2026

NRF2 as a Therapeutic Target in Dermatological Disorders: Mechanisms and Molecules.

NRF2 as a Therapeutic Target in Dermatological Disorders: Mechanisms and Molecules.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 03, 2026

CHI3L1 Expression in Neutrophils and Plasma of Multiple Sclerosis Patients: Implications for Pathogenesis and a Potential Biomarker.

CHI3L1 Expression in Neutrophils and Plasma of Multiple Sclerosis Patients: Implications for Pathogenesis and a Potential Biomarker.

Journal: International journal of molecular sciences

Published: February 01, 2026

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.

Journal: Journal of clinical medicine

Published: February 01, 2026

Dimethyl fumarate attenuates subcutaneous adipose tissue inflammation in psoriasis.

Dimethyl fumarate attenuates subcutaneous adipose tissue inflammation in psoriasis.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 25, 2026

T-2 Toxin Neurotoxicity: Molecular Mechanisms and Emerging Chemoprotective Strategies.

T-2 Toxin Neurotoxicity: Molecular Mechanisms and Emerging Chemoprotective Strategies.

Journal: Antioxidants (Basel, Switzerland)

Published: December 24, 2025

Nrf2 modulates the IRF7-SLC31A1 axis to suppress neuronal cuproptosis after traumatic brain injury.

Nrf2 modulates the IRF7-SLC31A1 axis to suppress neuronal cuproptosis after traumatic brain injury.

Journal: Experimental neurology

Published: December 21, 2025

Showing 1-12 of 1,784

Last Updated: 04/28/2026